Emerging Technologies for Heart Diseases was conceived to cover the recent extensive literature on current and novel therapeutic options for cardiac patients. The first volume is dedicated to heart failure and valvular disorders, and the second covers myocardial ischemia and arrhythmias. The clinical topic is addressed in several chapters divided according to the therapeutic approach (mechanical or electrical device-based, or cell and gene-based). Each of the 46 chapters focuses on clinically available solutions, new therapies currently under evaluation in clinical trials, promising preclinical technologies, and emerging concepts and innovations that have not yet been tested in a preclinical model. Also, the book discusses future challenges and opportunities for clinical implementation. Lessons learned from abandoned experimental practices are also covered, giving the readers the widest possible perspective of current therapeutic dilemmas.
Overall, this textbook was designed for physicians who want to stay up-to-date with current therapies and those of the future, for biomedical companies, and for those who wish to broaden their knowledge of new cardiovascular therapeutic options.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
SECTION 5: Treatment of ischemic heart disease 24. Coronary Balloon Angioplasty, Stenting, and Bioabsorbable Scaffolds 25. Coronary thrombectomy 26. Coronary atherectomy and treatments for calcified coronary lesions 27. Treatment of chronic total occlusion 28. Minimally-invasive device-based approaches for improving cardiac perfusion 29. Gene therapy approaches to cardiac neovascularization and protection from ischemiaSECTION 6: Treatment and prevention of ventricular tachyarrhythmias 30. The past, present and future of implantable electrical defibrillators 31. Electrophysiological mapping and cardiac ablation therapy for the prevention of ventricular arrhythmias 32. Gene and cell therapy approaches for the prevention and treatment of ventricular arrhythmia
SECTION 7: Treatment and prevention of supraventricular tachyarrhythmias 33. Ablation therapy and implantable device-based approaches for supraventricular arrhythmias 34. Gene and cell-based therapies for the prevention and treatment of supraventricular arrhythmias
SECTION 8: Treatment and prevention of bradyarrhythmias 35. Cardiac rhythm devices of today and tomorrow 36. Molecular therapies for bradyarrhythmias 37. Cell therapy approaches for treatment of bradyarrhythmias 38. Optogenetics for cardiac pacing and termination of arrhythmias 39. Non-optognetic approaches for leadless cardiac pacing
SECTION 9: Flexible electronics for cardiac monitoring and therapy 40. Organ Conformal Electronics for Cardiac Therapeutics
SECTION 10: Device-based therapies for prevention of cerebral embolization 41. Embolic protection devices for stroke prevention during cardiac interventions 42. Percutaneous closure of the left atrial appendage for stroke prevention 43. Devices for continuous embolic protection
SECTION 11: Noninvasive methods for structural heart defects 44. Transcatheter closure of atrial septal defect in adults 45. Catheter-based treatments for ventricular septal defects
SECTION 12: Novel treatments for hypertension 46. Non-pharmacological therapies for uncontrolled hypertension
Authors
Udi Nussinovitch Applicative Cardiovascular Research Center (ACRC) and Department of Cardiology, Meir Medical Center, affiliated to Tel Aviv University, Israel. Udi Nussinovitch, MD, PhD graduated from the Sackler Faculty of Medicine, Tel Aviv University, training at the Sheba Medical Center, Rambam Healthcare Center and Meir Medical Center, while concurrently graduating with a PhD in cardiac electrophysiology from the Technion Institute of Technology, Israel.Dr Nussinovitch has dedicated his research to investigating novel therapeutic approaches for cardiac disorders and the modulation of the cardiac electrophysiologic substrate for therapeutic purposes. He serves as director of the Applicative Cardiovascular Research Center (ACRC), affiliated to Tel Aviv University.
Dr Nussinovitch founded several biotech companies, and has been the recipient of several research awards. He carries out his clinical work at the Meir Medical Center, a medical facility and leading referral center in Israel.
